160 related articles for article (PubMed ID: 15456490)
21. A Common Missense Variant Causing Factor XI Deficiency and Increased Bleeding Tendency in Maine Coon Cats.
Kuder H; Dickeson SK; Brooks MB; Kehl A; Müller E; Gailani D; Giger U
Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627175
[TBL] [Abstract][Full Text] [Related]
22. An allosteric disulfide bond is involved in enhanced activation of factor XI by protein disulfide isomerase.
Zucker M; Seligsohn U; Yeheskel A; Mor-Cohen R
J Thromb Haemost; 2016 Nov; 14(11):2202-2211. PubMed ID: 27575053
[TBL] [Abstract][Full Text] [Related]
23. Role of platelets in regulating activated coagulation factor XI activity.
Reitsma SE; Pang J; Raghunathan V; Shatzel JJ; Lorentz CU; Tucker EI; Gruber A; Gailani D; McCarty OJT; Puy C
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C365-C374. PubMed ID: 33471623
[TBL] [Abstract][Full Text] [Related]
24. Defective binding of factor XI-N248 to activated human platelets.
Sun MF; Baglia FA; Ho D; Martincic D; Ware RE; Walsh PN; Gailani D
Blood; 2001 Jul; 98(1):125-9. PubMed ID: 11418471
[TBL] [Abstract][Full Text] [Related]
25. Gene targeting in hemostasis. factor XI.
Gailani D
Front Biosci; 2001 Feb; 6():D201-7. PubMed ID: 11171549
[TBL] [Abstract][Full Text] [Related]
26. Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen.
Bar Barroeta A; Marquart JA; Bakhtiari K; Meijer AB; Urbanus RT; Meijers JCM
J Thromb Haemost; 2022 Nov; 20(11):2538-2549. PubMed ID: 35815349
[TBL] [Abstract][Full Text] [Related]
27. Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX.
Sun MF; Zhao M; Gailani D
J Biol Chem; 1999 Dec; 274(51):36373-8. PubMed ID: 10593931
[TBL] [Abstract][Full Text] [Related]
28. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation.
Baird TR; Walsh PN
J Biol Chem; 2002 Oct; 277(41):38462-7. PubMed ID: 12167623
[TBL] [Abstract][Full Text] [Related]
29. An update on factor XI structure and function.
Mohammed BM; Matafonov A; Ivanov I; Sun MF; Cheng Q; Dickeson SK; Li C; Sun D; Verhamme IM; Emsley J; Gailani D
Thromb Res; 2018 Jan; 161():94-105. PubMed ID: 29223926
[TBL] [Abstract][Full Text] [Related]
30. Structural and functional features of factor XI.
Gailani D; Smith SB
J Thromb Haemost; 2009 Jul; 7 Suppl 1(Suppl 1):75-8. PubMed ID: 19630773
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect.
Guella I; Soldà G; Spena S; Asselta R; Ghiotto R; Tenchini ML; Castaman G; Duga S
Thromb Haemost; 2008 Mar; 99(3):523-30. PubMed ID: 18327400
[TBL] [Abstract][Full Text] [Related]
32. Characterisation of blood coagulation factor XI T475I.
McVey JH; Lal K; Imanaka Y; Kemball-Cook G; Bolton-Maggs PH; Tuddenham EG
Thromb Haemost; 2005 Jun; 93(6):1082-8. PubMed ID: 15968392
[TBL] [Abstract][Full Text] [Related]
33. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin.
Walsh PN
Thromb Haemost; 2001 Jul; 86(1):75-82. PubMed ID: 11487044
[TBL] [Abstract][Full Text] [Related]
34. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor.
Puy C; Tucker EI; Matafonov A; Cheng Q; Zientek KD; Gailani D; Gruber A; McCarty OJ
Blood; 2015 Feb; 125(9):1488-96. PubMed ID: 25587039
[TBL] [Abstract][Full Text] [Related]
35. Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.
Marcinkiewicz MM; Sinha D; Walsh PN
J Biol Chem; 2012 Feb; 287(9):6187-95. PubMed ID: 22207756
[TBL] [Abstract][Full Text] [Related]
36. Predictive value for increased activated factor XI activity in acute venous thromboembolism.
Nagy M; Robles AP; Visser M; Koeck T; Ten Cate V; Ten Cate-Hoek AJ; Schwers S; Heitmeier S; Ten Cate H; Wild PS; Spronk HMH
J Thromb Haemost; 2023 Jun; 21(6):1610-1622. PubMed ID: 37003466
[TBL] [Abstract][Full Text] [Related]
37. Amidolytic assay of factor XI in human plasma--significance of kallikrein for the activity measured.
Briseid K; Hoem NO; Johannesen S; Haug K
Thromb Res; 1995 May; 78(3):239-50. PubMed ID: 7631304
[TBL] [Abstract][Full Text] [Related]
38. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia.
Minnema MC; Pajkrt D; Wuillemin WA; Roem D; Bleeker WK; Levi M; van Deventer SJ; Hack CE; ten Cate H
Blood; 1998 Nov; 92(9):3294-301. PubMed ID: 9787166
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
40. Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.
Kearney KJ; Butler J; Posada OM; Wilson C; Heal S; Ali M; Hardy L; Ahnström J; Gailani D; Foster R; Hethershaw E; Longstaff C; Philippou H
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33397811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
